@FiercePharma: Top story on our website this A.M.: Who are the richest biopharma execs? Not all the usual suspects. Article | Follow @FiercePharma
> Johnson & Johnson's ($JNJ) Janssen unit said its arthritis drug Stelara won approval from the FDA to treat adults with psoriatic arthritis; it was previously approved for patients with moderate-to-severe plaque psoriasis. Report
> GlaxoSmithKline ($GSK) won a new indication in Europe for its Revolade drug, to treat low platelet counts in patients with chronic hepatitis C infection. Report
> Boehringer Ingelheim and Eli Lilly's ($LLY) Trajenta diabetes drug proved well tolerated in a broad variety of patients, including elderly patients with kidney problems, a study found. Report
> Sanofi's ($SNY) new diabetes drug Lyxumia delivered the best results as an add-on to basal insulin in Type 2 diabetes patients with well-controlled fasting blood sugar, a study found. Release
> The Chicago Mercantile Exchange says it will no longer accept delivery of Zilmax-treated cattle after Oct. 7; it's the latest organization to refuse cattle fed the Merck ($MRK) growth stimulant. Report
> Sanofi's new oral flea treatment for dogs, NexGard Chewables, won FDA approval. Release (PDF) | Report
> A new study found that cholesterol-fighting statin drugs may increase the risk of cataracts. Report
@FierceMedDev: At AdvaMed, European regulations are on many CEOs' minds. Editor's corner | Follow @FierceMedDev
@MarkHFierce: The debt ceiling/budget fight has given an opening to device tax opponents. They hope for a repeal before year-end. More | Follow @MarkHFierce
@MichaelGFierce: Alnylam heralds positive results for RNAi amyloidosis drug. Story | Follow @MichaelGFierce
> Sequenom looks to unload analysis biz. Article
> Edwards wins FDA nod to expand Sapien label. Story
> Federal debt ceiling fight opens window for device tax opponents. Report
> Medtronic's tech halves atrial fibrillation risk. More
Biotech News
@FierceBiotech: The 2013 Fierce 15 biotech execs take a bow. Editor's corner | Follow @FierceBiotech
@JohnCFierce: Some folks might want to adjust their timelines on ARN-509. PhIII is coming. Item | Follow @JohnCFierce
@DamianFierce: Thanks to everyone cheering my trip to FierceBiotech! | Follow @DamianFierce
> SEC charges another biotech profiteer linked to insider trading scheme. More
> Ex-InterMune CEO's press-release pomp could leave legal legacy. Story
> AbbVie continues deal spree with $405M CF tie-up with Galapagos. News
Pharma Manufacturing News
@EricPFierce: After sales of Bydureon came up short, Bristol-Myers, AstraZeneca report manufacturing has too. Article | Follow @EricPFierce
> FDA warns Agila plant over torn gloves. Story
> Pharma squares off against compounders in lobbying fight. News
> J&J wins a bright spot after string of recalls. More
> FDA beefs up Indian staff in face of serious problems. Story
> U.K., Australia gather FDA intel on Ranbaxy ban. Report
Biotech Research News
@EmilyMFierce: $3.7M NIH program to fund biomedical research training. Item | Follow @EmilyMFierce
> Stem cell therapy protects vision in preclinical retinal disease study. More
> Pre-leukemia drug shows brain tumor regression in mice. News
> Stem cell reprogramming made easier by removing one protein. Report
> New compound kills tuberculosis bacterium in lab tests. Story
> NIH launches $45M Alzheimer's research effort, awards funds to 3 preclinical studies. Article
And Finally... A major study flagged sex differences in patients' blood-glucose control with Type 1 diabetes. Report